Shares of Dermira Inc. (NASDAQ:DERM) rose 4.4% during mid-day trading on Wednesday . The company traded as high as $34.38 and last traded at $33.80, with a volume of 95,046 shares. The stock had previously closed at $32.39.

DERM has been the topic of a number of recent research reports. Zacks Investment Research raised Dermira from a “sell” rating to a “hold” rating in a report on Tuesday, June 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $42.00 price target (up previously from $38.00) on shares of Dermira in a report on Tuesday, May 10th. Leerink Swann reaffirmed a “buy” rating and issued a $47.00 price target (up previously from $46.00) on shares of Dermira in a report on Thursday, June 2nd. Finally, Wedbush raised their price target on Dermira from $42.00 to $46.00 and gave the company an “outperform” rating in a report on Thursday, June 2nd. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $40.71.

The firm’s 50-day moving average price is $30.07 and its 200 day moving average price is $26.45. The stock’s market cap is $1.03 billion.

Dermira (NASDAQ:DERM) last issued its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.95) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.94) by $0.01. Equities analysts anticipate that Dermira Inc. will post ($3.51) earnings per share for the current year.

In other Dermira news, VP Christopher M. Griffith sold 1,303 shares of the business’s stock in a transaction dated Friday, July 15th. The stock was sold at an average price of $30.02, for a total transaction of $39,116.06. Following the completion of the sale, the vice president now owns 44,941 shares of the company’s stock, valued at $1,349,128.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eugene A. Bauer sold 2,500 shares of the business’s stock in a transaction dated Monday, May 2nd. The shares were sold at an average price of $25.09, for a total value of $62,725.00. The disclosure for this sale can be found here.

Other hedge funds recently added to or reduced their stakes in the company. Jennison Associates raised its stake in Dermira by 98.7% in the third quarter. Jennison Associates now owns 1,013,343 shares of the biopharmaceutical company’s stock valued at $23,651,000 after buying an additional 503,237 shares in the last quarter. Morgan Stanley raised its stake in Dermira by 82.2% in the fourth quarter. Morgan Stanley now owns 42,767 shares of the biopharmaceutical company’s stock valued at $1,480,000 after buying an additional 19,299 shares in the last quarter. Finally, Jennison Associates LLC raised its stake in Dermira by 8.3% in the fourth quarter. Jennison Associates LLC now owns 1,097,201 shares of the biopharmaceutical company’s stock valued at $37,974,000 after buying an additional 83,858 shares in the last quarter.

Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.